Ferric pyrophosphate citrate - Rockwell Medical Technologies

Drug Profile

Ferric pyrophosphate citrate - Rockwell Medical Technologies

Alternative Names: FePPi dialysate - Rockwell Medical Technologies; FPC - Rockwell Medical Technologies; Iron supplemented dialysate - Rockwell Medical Technologies; SFP - Rockwell Medical Technologies; Triferic; Triferic® Iron Delivery Therapy; Triferic® IV Solution; Triferic® Intravenous Solution; Triferic® PD Solution; Triferic® Peritoneal Dialysis Solution; Triferic® Total Parenteral Nutrition Solution; Triferic® TPN Solution

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator Ash Access Technology; Charak LLC
  • Developer Rockwell Medical Technologies
  • Class Antianaemics; Diphosphates; Heavy metals
  • Mechanism of Action Iron replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Iron deficiency anaemia
  • Phase I Renal failure

Most Recent Events

  • 01 Jan 2017 Rockwell Medical Technologies completes a phase-I/II trial in Iron deficiency anaemia (In infants, In children, In adolescents with end stage renal disease) in USA (IV) (NCT02595437)
  • 04 Oct 2016 Pharmacokinetic data from a phase I trial in Iron deficiency anaemia (in volunteers) released by Rockwell Medical Technologies
  • 28 Sep 2016 Rockwell Medical Technologies plans a phase I trial for Renal failure (peritoneal dialysis) in USA (NCT02909153)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top